title: Effects of stromal cell-derived factor-1 and survivin gene polymorphisms             on gastric cancer risk.
abstract: Stromal-cell derived factor-1 (SDF-1), a CXC chemokine, is important for             growth, angiogenesis and metastasis of tumor cells. The SDF1-3'A polymorphism             has been investigated in various types of cancer; however, no information is currently             available on its role in gastric cancer. Survivin is a member of the inhibitor             of apoptosis family of proteins and has a genetic polymorphism (-31G/C) located             in the CDE/CHR repressor element of its promoter. In this study, 88 gastric cancer             patients and 480 normal healthy control subjects were investigated for the genotype             and allelic SDF1-3'A and survivin -31G/C frequencies using polymerase chain reaction‑restriction             fragment length polymorphism. The SDF1-3'A genotype frequencies for GG, GA and             AA were 44.32, 48.86 and 6.92% in patients and 42.71, 47.71 and 9.58% in healthy             subjects, respectively. GA+AA genotype frequency and A allele distribution were             not identified as significantly different between gastric cancer cases and controls.             The survivin frequencies for GG, GC and CC were 20.45, 50 and 29.54% in patients             and 33.96, 45 and 21.04% in healthy subjects, respectively. The C carriers (GC+CC             genotype) and the C allele were over-represented among the gastric cancer cases             (P=0.013 and P=0.0083, respectively). Overall, no statistically significant association             was identified for SDF-1 and survivin gene examined alleles and genotypes and             any parameter investigated, (e.g., stage, differentiation status and survival).             The survivin promoter -31G/C polymorphism may confer an increased susceptibility             to gastric cancer, while the SDF1-3'A polymorphism may not be a candidate genetic             variant to select individuals at higher risk of developing gastric cancer.
authors.affiliation: First Surgical Department, Tzaneion Hospital, Piraeus, Greece.
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Liarmakopoulos
authors.forename: George
authors.initials: G
authors.lastname: Theodoropoulos
authors.forename: Anna
authors.initials: A
authors.lastname: Vaiopoulou
authors.forename: Spyros
authors.initials: S
authors.lastname: Rizos
authors.forename: Gerasimos
authors.initials: G
authors.lastname: Aravantinos
authors.forename: Gregory
authors.initials: G
authors.lastname: Kouraklis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Nikiteas
authors.forename: Maria
authors.initials: M
authors.lastname: Gazouli
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D054377:Chemokine CXCL12 / Q000235:genetics*; D004198:Disease Susceptibility; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D013274:Stomach Neoplasms / Q000235:genetics*; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D054377:Chemokine CXCL12; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin